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Abstract
Background:  Congenital fibrosis of the extraocular muscles types 1 and 3 (CFEOM1/CFEOM3) are autosomal
dominant strabismus disorders that appear to result from maldevelopment of ocular nuclei and nerves. We previously
reported that most individuals with CFEOM1 and rare individuals with CFEOM3 harbor heterozygous mutations in
KIF21A. KIF21A encodes a kinesin motor involved in anterograde axonal transport, and the familial and de novo mutations
reported to date predictably alter one of only a few KIF21A amino acids – three within the third coiled-coil region of
the stalk and one in the distal motor domain, suggesting they result in altered KIF21A function. To further define the
spectrum of KIF21A mutations in CFEOM we have now identified all CFEOM probands newly enrolled in our study and
determined if they harbor mutations in KIF21A.
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Results: Sixteen CFEOM1 and 29 CFEOM3 probands were studied. Three previously unreported de novo KIF21A
mutations were identified in three CFEOM1 probands, all located in the same coiled-coil region of the stalk that contains
all but one of the previously reported mutations. Eight additional CFEOM1 probands harbored three of the mutations
previously reported in KIF21A; seven had one of the two most common mutations, while one harbored the mutation in
the distal motor domain. No mutation was detected in 5 CFEOM1 or any CFEOM3 probands.
Conclusion: Analysis of sixteen CFEOM1 probands revealed three novel KIF21A mutations and confirmed three
reported mutations, bringing the total number of reported KIF21A mutations in CFEOM1 to 11 mutations among 70
mutation positive probands. All three new mutations alter amino acids in heptad repeats within the third coiled-coil
region of the KIF21A stalk, further highlighting the importance of alterations in this domain in the etiology of CFEOM1.
Background
Congenital fibrosis of the extraocular muscles type 1
(CFEOM1; MIM#135700) is a congenital eye movement
disorder inherited as an autosomal dominant trait and
characterized by bilateral ptosis and bilateral ophthalmo-
plegia with the globes fixed downward and unable to be
raised above the horizontal midline. Affected individuals
have dysplasia of the levator palpebrae superioris and
superior rectus muscles that elevate the eyelid and globe,
respectively, absence of the superior division of the oculo-
motor nerve that innervates these muscles, and loss of cor-
responding motoneurons in the midbrain oculomotor
nucleus [1,2]. CFEOM3 (MIM#600638 & MIM#607034)
is a similar disorder with a somewhat broader phenotype;
in pedigrees with autosomal dominant CFEOM3, some
individuals may have the characteristic clinical features of
CFEOM1, but at least one affected family member does
not meet CFEOM1 criteria. S/he may be unilaterally
affected, have one or both globes fixed at or above the
midline, or have residual upgaze [3-5].
Most individuals with CFEOM1 and rare individuals with
CFEOM3 harbor heterozygous mutations in the develop-
mental kinesin, KIF21A [6-8]. Kinesins (KIFs) are molecu-
lar motors that transport cargo along microtubules and, in
neurons, are responsible for anterograde axonal transport.
In mouse development, Kif21a expression begins ~E10.5,
the time at which the oculomotor nerve and extraocular
muscles are developing [6], and is expressed in neurons
[9]. The KIF21A cargo is not known.
The 38 exons of KIF21A encode a 1674 amino acid pro-
tein. Remarkably, only 8 unique mutations altering only
4 amino acids have been identified among the 56
CFEOM1 and 3 CFEOM3 probands harboring KIF21A
mutations reported to date by us [6-8] and by others [13-
16]. Three of these amino acid residues are located in hep-
tad repeats within the third coiled-coil region of the
KIF21A stalk, and one of these, R954, is altered in ≥ 86%
of all individuals with KIF21A mutations reported to date.
Two unrelated probands with CFEOM1 harbor a muta-
tion that alters the fourth residue, located at the end of the
motor domain. To further expand the definition of
KIF21A mutations that result in CFEOM, we now report
the mutations we have identified in CFEOM probands
who were enrolled in our study since our previous muta-
tion reports [6-8].
Results
Since our previous reports of KIF21A  mutations in
CFEOM [6-8], we have enrolled an additional 16
CFEOM1 probands of varying ethnicities, six of whom
segregate CFEOM1 within their family as a dominant trait
(Table 1, Fig. 1A). We have also enrolled 13 familial and
16 sporadic CFEOM3 probands.
The affected members of all of the pedigrees that segregate
CFEOM1 as a dominant trait have classic CFEOM1 with-
out additional features. Three probands with sporadic
CFEOM1, however, have additional clinical features. RY
has evidence of aberrant innervation with elevation of the
left eye and adduction of the right eye while chewing, and
SK has bilateral Marcus Gunn jaw winking phenomenon
and pupils that respond sluggishly to light. These addi-
tional features are similar to the aberrant eye movements
and Marcus Gunn phenomenon we have reported previ-
ously in a subset of CFEOM1 patients harboring KIF21A
mutations [8,17]. Together with our MR imaging data [2],
this clinical data has supported the presence of wide-
spread dysinnervation in a subset of CFEOM1 patients
who harbor KIF21A mutations. Individual RZ, however,
has facial weakness and brain MR imaging that reveals
mild thinning of the splenium of the corpus collosum,
features that have not been associated with KIF21A muta-
tions.
We identified heterozygous KIF21A mutations in 11 of the
16 CFEOM1 probands, and none of the CFEOM3
probands. Eight of the CFEOM1 probands harbor previ-
ously reported KIF21A mutations: 5 harbor the most com-
mon CFEOM1 mutation, 2860C>T, which alters the first
nucleotide of the triplet codon encoding amino acid resi-
due 954 (R954W); 2 harbor the second most common
mutation, 2861G>A, which alters the second nucleotide
of the same triplet codon (R954Q); while 1 harbors the
1067T>C mutation which alters a residue located at theBMC Genetics 2007, 8:26 http://www.biomedcentral.com/1471-2156/8/26
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end of the kinesin motor domain (M356T), and is the
third proband with this mutation we have identified. In
all familial cases, the mutations co-segregated with
CFEOM1 and were absent in unaffected family members.
In the one case of sporadic CFEOM1 for which we had the
participation of both parents (pedigree IW), the mutation
was de novo (Table 1).
Three previously unreported KIF21A  mutations were
identified in three individuals with sporadic CFEOM1.
Probands from pedigrees SK, RY, and XF harbor de novo
heterozygous  KIF21A  missense mutations 2861G>A
(R954L), 2830G>C (E944Q), and 3022G>C (A1008P),
respectively (Fig. 2A). These three mutations were not
found in the parents of the probands (Fig. 2A), or in 162
control chromosomes of mixed ethnicity. All three muta-
tions are predicted to result in nonconservative amino
acid substitutions. Residues R954 and E944 are conserved
in mouse, rat, D. melanogaster, and C. elegans, while A1008
is conserved between human, mouse and rat (Fig. 2B).
Discussion
We have re-confirmed three of the reported 'hotspot'
CFEOM1 mutations in KIF21A  in eight additional
probands, and have identified three previously unre-
ported heterozygous de novo KIF21A mutations in three
individuals with sporadic CFEOM1. Combining this with
the published data, all 11 KIF21A mutations identified to
date in CFEOM probands are missense mutations, and are
predicted to result in the alteration of only 6 of the 1674
amino acid residues that make up the KIF21A protein
(summarized in Table 2). All 11 nucleotides and all 6
altered amino acid residues are identical in mouse and
human, and the amino acid residues are highly conserved
in other species. Moreover, 10 of the 11 mutations,
including all 3 new mutations presented in this report,
alter amino acids in the third coiled-coil region of the
KIF21A stalk (Fig. 2C). The 2861G>T substitution found
in pedigree SK becomes the third CFEOM1 mutation to
alter KIF21A residue R954, and mutations of this triplet
codon currently account for 84% of KIF21A mutations in
CFEOM. In contrast, 4 of the 11 mutations alter residue
M947 but account for only 6% of the total reported muta-
tions.
The structure of the KIF21A protein includes an N-termi-
nal motor domain, a central stalk, and C-terminal tail
domain (Fig. 2C). The motor domain contains the bind-
ing site for the microtubule, and tends to be highly con-
served. The tail domain diverges among KIFs, and
typically contains the site where cargo is loaded, often via
an adaptor/scaffolding protein or protein complex [10].
The stalk domain is a flexible connector between the
motor and tail that contains α-helical coiled-coil repeats.
Typically, the stalk repeats near the motor domain of
kinesins are the site of KIF homo- or heterodimerization,
permitting two KIF motors to 'walk' down the microtu-
bule. In addition, in some KIFs the coiled-coil domains
toward the C-terminal end of the stalk have been demon-
strated to interact with cargo [11,12].
The amino acids in the coiled-coil region of the stalk form
heptad repeats. Within the repeated heptad consensus
sequence, the first (a) and fourth (d) positions are gener-
ally nonpolar or hydrophobic amino acids, and when the
coiled-coil regions of two proteins interact, these posi-
tions are typically internalized and stabilize the dimeric
structure. The three amino acid residues in the KIF21A
stalk previously reported to be altered in CFEOM (M947,
R954, I1010) are each located at the (a) position of hep-
Table 1: Summary of CFEOM1 probands included in report.
Pedigree Inheritance Ethnicity KIF21A mutation De novo KIF21A linkage FEOM3 linkage Additional Features
PG AD Caucasian 1067T>C c/w linkage
KR AD Hispanic 2860C>T linked
TG AD Caucasian 2860C>T c/w linkage
NH AD Turkish 2861G>A
NJ AD Caucasian 2861G>A
LX AD Iranian None Reduced penetrance Reduced penetrance
RY Sporadic Caucasian 2830G>C Yes +
IW Sporadic Caucasian 2860C>T Yes
JT Sporadic Caucasian 2860C>T
IP Sporadic Caucasian 2860C>T
SK Sporadic Caucasian 2861G>T Yes +
XF Sporadic Caucasian 3022G>C Yes
NG Sporadic Turkish None
RZ Sporadic African None +
RX Sporadic Caucasian None
SY Sporadic Caucasian None
c/w linkage = consistent with linkage; Reduced penetrance = consistent with linkage with reduced penetrance.BMC Genetics 2007, 8:26 http://www.biomedcentral.com/1471-2156/8/26
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tad repeats within the coiled-coil domain (Fig. 2C), and
may normally modulate the assembly and stability prop-
erties of the protein structure and interaction. The novel
mutation, R954L, identified in SK and the recurrent muta-
tions R954W and R954Q identified in seven probands in
this study strengthen our hypothesis that the highly con-
served and positively charged arginine residue R954 is an
important site for KIF21A function. Two of the new muta-
tions, 2830G>C and 3022G>C, however, are the first
CFEOM mutations within the coiled-coil domain that
alter amino acids not in the (a) position of heptad repeats,
altering instead residues in the (e) and (f) positions,
respectively (Fig. 2C). These remaining positions (b, c, e,
f, g) in the heptad repeat are generally exposed on the sur-
face of the protein, and these new mutations demonstrate
that their disruption can also result in the CFEOM1 phe-
notype.
The specificity of CFEOM mutations for particular resi-
dues within one C-terminal coiled-coil domain of the
KIF21A stalk suggests that these mutations alter a critical
and specific function of this domain [18,19]. They may
alter dimerization between KIF21A and itself or another
kinesin, may interfere with binding of a specific cargo
complex, or may result in binding of an alternative part-
ner. In any of these cases, the likely result is failure of
delivery of a cargo that is important to the development of
the oculomotor axis.
We sequenced all remaining KIF21A exons and intron-
exon boundaries in one autosomal dominant CFEOM1
pedigree (LX), four sporadic CFEOM1 probands (NG, RZ,
RX, and SY), and all of the CFEOM3 probands, and did
not identify any KIF21A mutations. Co-segregation analy-
sis of the CFEOM1 phenotype in pedigree LX with mark-
ers at the FEOM1, FEOM2, and FEOM3 loci was then
investigated. Although analysis was limited by the enroll-
ment of only one of the three affected siblings, this
affected sibling shares the same paternal allele with three
of his unaffected siblings at both the FEOM1 and FEOM3
loci (Fig. 1B). Reduced penetrance has not been reported
for a CFEOM1 pedigree harboring a KIF21A mutation,
Pedigrees with autosomal dominant inheritance of CFEOM1 Figure 1
Pedigrees with autosomal dominant inheritance of CFEOM1. Black circles/squares indicate clinically affected individu-
als, and plus signs denote individuals who participated in this study. (A) Pedigrees harboring KIF21A mutations: pedigrees KR 
and TG harbor 2860C>T; pedigrees NH and NJ harbor 2861G>A; pedigree PG harbors 1067T>C. (B) Haplotype analysis of 
pedigree LX at the KIF21A locus. Genotyping data and schematic segregating haplotype bars for chromosome 12cen markers 
are shown below the symbol for each participant. A black bar indicates the haplotype passed from the affected father to his 
affected daughter. This haplotype is also inherited by three of the four unaffected siblings who participated in the study. A 
KIF21A mutation was not detected in this pedigree.
(A)      PG                                      KR                                   TG                  NH               NJ 
(B)                             LX                           BMC Genetics 2007, 8:26 http://www.biomedcentral.com/1471-2156/8/26
Page 5 of 8
(page number not for citation purposes)
supporting our hypothesis that this pedigree harbors a
disease-causing mutation in a different gene. Finally, to
rule out compound heterozygous mutations in PHOX2A,
the proband was screened for mutations and none were
identified (data not shown). The 4 sporadic CFEOM1
probands without mutations may harbor mutations at the
FEOM3 locus on chromosome 16, as we have identified
rare CFEOM1 pedigrees that map to this locus [6,20].
Alternatively, they could harbor mutations in the pro-
moter of KIF21A or in another unidentified CFEOM gene.
Nucleotide sequence, amino acid positions, and conservation of the three new KIF21A mutations Figure 2
Nucleotide sequence, amino acid positions, and conservation of the three new KIF21A mutations. (A) Hetero-
zygous de novo KIF21A mutations in probands of pedigrees RY, SK and XF. Sequence chromatographs of the unaffected parents 
are normal (top 2 rows), while sequence chromatographs of the affected offspring with CFEOM1 (bottom row) each reveals a 
heterozygous KIF21A mutation. The normal sequence and corresponding amino acid residues are indicated under each father's 
sequence chromatograph (black), while the mutation and resulting amino acid substitution are denoted under each affected 
proband's sequence (red). (B) Portions of the human KIF21A amino acid sequence that surround each of the reported 
CFEOM1 mutations aligned with homologous/paralogous sequence. Positions a-g of heptad repeat sequence are denoted. Iden-
tical amino acid residues are highlighted in dark gray; similar residues are highlighted in light grey. The residues altered by the 
three new mutations are boxed in red, and the previously reported mutations are boxed in blue. (C) Predicted KIF21A protein 
structure. The amino acid residues altered by the 3 new heterozygous mutations are depicted in red with red arrows above 
the protein pointing to their predicted positions. The 8 previously reported KIF21A mutations are indicated in blue and their 
locations are indicated by blue arrows above the protein.
Pedigree RY
Affected
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Finally, we did not identify mutations in any of the
CFEOM3 probands, demonstrating again that KIF21A
mutations are a rare cause of this form of CFEOM. Given
the similarities of the CFEOM1 and CFEOM3 phenotypes
and the partial overlap in their genetic etiologies, one can
hypothesize that the unidentified FEOM3 gene on chro-
mosome 16 may interact with KIF21A and/or function in
the same developmental pathway.
Conclusion
Analysis of sixteen CFEOM1 probands revealed three
novel KIF21A  mutations and confirmed three reported
mutations, bringing the total number of reported KIF21A
mutations in CFEOM1 to 11 mutations among 70 muta-
tion positive probands. All three new mutations alter
amino acids in heptad repeats within the third coiled-coil
region of the KIF21A stalk, further highlighting the impor-
tance of alterations in this domain in the etiology of
CFEOM1. Absence of KIF21A mutations in some patients
with CFEOM1 confirms the genetic heterogeneity of this
clinical phenotype.
Methods
For this study, we identified in our database all CFEOM
probands ascertained since our previous reports [6-8]. All
affected individuals and participating family members
were enrolled in our ongoing research study of congenital
eye movement disorders approved by the Children's Hos-
pital Boston Institutional Review Board. Informed con-
sent was obtained after explanation of the nature and
possible consequences of the study, and each participant
donated a blood or saliva sample from which genomic
DNA was extracted using a standard protocol. The
research followed the tenets of the Declaration of Hel-
sinki.
High-molecular weight genomic DNA was extracted from
blood and salivary samples using the Puregene kit (Gen-
tra), and the purifier solution kit (DNA Genotek), respec-
tively. KIF21A exons 8, 20 and 21 and their exon-intron
boundaries were first amplified from genomic DNA of
each proband using the polymerase chain reaction (PCR)
and HotStar Taq DNA polymerase (Qiagen, Germany), as
these three exons contain all CFEOM1 mutations reported
to date. The resulting amplicons were then directly
sequenced on an ABI 3730 Sequence Analyzer (Applied
Biosystems, Foster City, CA). If a mutation was not iden-
tified within one of these three KIF21A exons, the remain-
ing 35 KIF21A  coding exons were amplified and each
amplicon analyzed by denaturing high-performance liq-
uid chromatography (DHPLC, Transgenomic, Inc.,
Omaha, NE) and/or direct sequencing. When a sequence
variant was identified in the proband of an autosomal
dominant pedigree, its co-segregation within the family
was confirmed. When a sequence variant was identified in
a sporadic case, parental DNA was amplified and
sequenced to determine if the mutation were de novo.
Primer sequences and PCR conditions are published [6].
To determine if a previously unreported sequence varia-
tion was a polymorphism, SNP databases were interro-
gated and each variation was looked for in a control panel
of 81 DNA samples (162 chromosomes) of mixed ethnic-
ity. PCR amplicons that included the variation were ana-
lyzed by either DHPLC using appropriate denaturing
temperatures and acetonitrile gradients, or by size analysis
following restriction digest by DraIII (New England
Table 2: Summary of KIF21A mutations reported in CFEOM probands to date.
Phenotype & Mutation Amino acid Previous Engle Lab Reports6–8 Other Lab's Reports13–16 Current Report Total % mutations
CFEOM1 Total 45 12 11 68/70 97%
1067 T>C M356T 2 0 1 3 4.0%
2830G> C E944Q 0 0 1 1 1.5%
2839A>G M947V 1 0 0 1 1.5%
2840T>C M947T 1 0 0 1 1.5%
2840T>G M947R 1 0 0 1 1.5%
2860C>T R954W 32 12 5 49 70%
2861G>A R954Q 6 0 2 8 11%
2861G>T R954L 0 0 1 1 1.5%
3022G>C A1008P 0 0 1 1 1.5%
3029T>C I1010T 2 0 0 2 3.0%
CFEOM3 Total 2 0 0 2/70 3%
2841G>A M947I 1 0 0 1 1.5%
2860C>T R954W 1 0 0 1 1.5%BMC Genetics 2007, 8:26 http://www.biomedcentral.com/1471-2156/8/26
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BioLabs, Ipswich, MA). DHPLC conditions and restriction
digestion condition are available on request. For any ped-
igree that segregated CFEOM1 in more than one family
member and in which a KIF21A mutation was not identi-
fied, co-segregation analysis was performed between the
CFEOM1 phenotype and fluorescently labeled microsatel-
lite markers spanning each of the three FEOM loci:
FEOM1 locus (D12S1648, D12S1692, D12S59,
D12S1067, D12S1048); FEOM2 locus (D11S4162,
D11S1314, D11S1369); and FEOM3 locus (D16S498,
D16S2621, D16S3121, D16S303). Fluorescently labeled
primers were purchased from Invitrogen, and amplicons
were generated by 30 cycles of PCR amplification contain-
ing 10–30 ng of genomic DNA in 5-μl reaction volumes of
Qiagen's Taq PCR Master Mix containing 2 pmol of each
fluorescent primer pair, 1 nmol each of dATP, dTTP,
dGTP, and dCTP, and 0.15 U Taq polymerase. The prod-
ucts were analyzed in an Applied Biosystems 3730 DNA
Analyzer. GenBank accession numbers. Human KIF21A
cDNA reference sequence is AY368076; human KIF21A
genomic reference sequences are AC084373, AC090668
and AC121334; Mouse Kif21a  cDNA sequence is
NM_016705 protein is NP_057914; Mouse Kif21b pro-
tein sequence is NP_064346; Rat Kif21 protein sequence
is XP_223090;  Drosophila melanogaster Kif21 protein
sequence is NP_609398;  Caenorhabditis elegans Klp-12
protein sequence is BAB18763.
Abbreviations
CFEOM1 = Congenital fibrosis of the extraocular muscles
type 1
CFEOM3 = Congenital fibrosis of the extraocular muscles
type 3
PCR = polymerase chain reaction
DHPLC = denaturing high-performance liquid chroma-
tography
SNP = single nucleotide polymorphism
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